SUNY Downstate Health Sciences University
Biotech Grows in Brooklyn
Incubator Company Profiles
AccelBio provides results for biotechnology applications and pharmaceutical outcomes with a focus on customized neurobiology discovery research. With AccelBio's expertise in molecular cell biology and animal work, it leverages premier bioassays in multiple formats, including high-throughput screens using chemically unique entities for drug discovery, and exclusive use of superior primary cells through Evergreen Biosciences. AccelBio's contract services enable the highest quality R&D focused on genetic models and disease pathways.
Contact: Jason Dictenberg, Ph.D., CEO (718-845-7374)
Accutar Biotechnology, Inc.
Accutar's focus is on hybrid method-based drug discovery.
Contact: Jie Fan, Founder & CEO (646-462-5083)
Applied Biological Laboratories Inc.
Applied Biological Laboratories Inc. is a biotechnology company committed to research, development, manufacturing and distribution of scientifically validated natural products.
Founded in 2016 to pursue novel techniques for harvesting solar energy, Aquaneers’ developed its nanotechnology-enabled Plasmonic Ribbon (PR) product as a platform material for optical energy conversion. It is used as a photothermal absorber in the AquaSol solar desalination systems under commercial development through DOE Phase II SBIR support. In collaboration with University and Industry partners, Aquaneers is developing advanced manufacturing techniques and industrial processes for the continuous, reel-to-reel manufacture of the Plasmonic Ribbon product.
AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. is a biotechnology company that develops non-systemic recombinant protein therapies for the treatment of gastrointestinal (GI) and infectious diseases. AzurRx's two leading therapeutics are: MS1819 Lipase (Phase IIa) for the treatment of severe malnutrition associated with Chronic Pancreatitis and Cystic Fibrosis; and AZX1101 (preclinical) which reduces the incidence of Clostridium difficile infection, one of the most common hospital acquired infections.
Contact: Martin Krusin, Vice President, Business Development (646-699-7855)
BioMolecular, Inc. is a leading technology, product and service provider for the life science community. The company has developed a variety of biological research reagents, such as ultra-speed clone vector, ultra-sensitive PCR system, one step Western blot and magic protein sample solution. These reagents are widely used in molecular biological research, drug discovery and clinical diagnosis. The company’s research services include customer gene expression, DNA and RNA purification, gDNA and cDNA library construction, PCR and gene clone, RT-PCR, clinical assay, primer and gene synthesis, DNA sequencing and contracting research project.
Contact: Gang Wu (917-362-0788) - email@example.com
CMP Scientific Corp.
CMP Scientific Corp. currently develops, manufactures, and sells nanoLC capillary columns and CE-ESI-MS ion sources. CMP Scientific is founded by experts in the analytical science field, especially the LC-MS and CE-MS coupling technologies. It seeks to become an industry leader as an analytical instrumentation company with five core products/services: nanoLC capillary columns, CE-ESI-MS ion sources, CE instruments, CE consumables, and CE-ESI-MS CRO service.
Contact: James (Qiangwei) Xia, Ph.D., CEO & Principal Scientist (718-360-7803)
Concarlo Holdings, LLC
Concarlo Holdings, LLC (Concarlo) is a start-up drug development company focused on
innovative therapeutics and diagnostics for unmet needs in oncology.
Contact: LisaMarie Casey - Info@concarlo.com
CortecNet is a stable isotopes company which identifies, develops, produces and markets innovative products in the fields of NMR, MS, MRI and PET to academia and industry. It is developing new synthesis methods to produce new labeled compounds with stable isotopes for hyperpolarized MRI applications.
Contact: Philippe Corcos, President & CEO - firstname.lastname@example.org
DrinkSavvy, Inc. is developing colorimetric chemical sensors that detect analytes, such as drugs, pathogens, bacteria, and explosives, for real-time detection in field use, without the need for secondary analysis using lab equipment or spectrometry. The chemical sensors will be embedded in plastic stirrers, straws and cups and provide a colorimetric signal to the consumer in order to prevent consumption of illicit drugs and ensuing drug-facilitated sexual assault and crime.
Contact: Brendan Walker
EpiBone, Inc. is a revolutionary bone reconstruction company that allows patients to grow their own bone. The company's pioneering technology utilizes a scan of the patient's bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.
Epi One Inc.
Epi One is a start up biotechnology company that aims to develop tests for the clinical diagnosis of diseases.
The need for an alternative to one’s own tissue for wound healing and repair has existed as long as reconstructive surgery itself. Fesarius Therapeutics is an early stage company that will develop and manufacture engineered skin and tissue replacement products using patented microsphere hydrogel technology invented by Dr. Jason Spector at the Weill Cornell Medical College Laboratory for Bioregenerative Medicine & Surgery.
Contact: Brett Spector, CEO – email@example.com
HemoGenyx LLC is a biopharmaceutical company developing new treatments for blood diseases. HemoGenyx’s research and core technology has already made it a leader in making traditional methods of patient conditioning and bone marrow transplants obsolete. The company's technology is an ideal platform for developing the next generation of blood disease treatments.HemoGenyx is committed to continued innovation to bridge the gap between basic research and clinical medicine.
HistoWiz, Inc. is a histopathology service company that processes, embeds, cuts, stains mouse tissue specimens and digitalizes the results for cancer researchers in academia and pharma. Unlike academic core facilities and CROs, HistoWiz guarantees a 3 day turn-around time and provides global access to whole-slide digital results, online collaboration features, low-cost digital data management, a cancer image database, and mouse cancer pathology expertise. The company's mission is to fight cancer cooperatively instead of individually by connecting scientists and doctors for online collaboration.
Contact: Ke Cheng (212-722-1456)
Immugenyx, LLC is a biopharmaceutical company developing new medicines and treatments that bring the curative power of immunotherapy to a greater number of patients suffering from otherwise incurable and often life-threatening diseases. To achieve this goal, Immugenyx uses a platform technology that leverages the unique properties of Advanced Hematopoietic Chimeras (AHC). The AHC developed by Immugenyx are used to create realistic human-like models of blood cancers, such as leukemia and lymphoma, as well as severe autoimmune diseases, such as multiple sclerosis, a plastic anemia and systemic lupus erythematosus (Lupus). Immugenyx is leveraging its proprietary AHC as a unique platform for the discovery and development of a variety of treatments, including immuno- and cell therapy, for these diseases.
International AIDS Vaccine Initiative (IAVI)
IAVI's AIDS Vaccine Design and Development Laboratory is a versatile facility designed to create novel immunogens, develop viral vectors, evaluate potency and advance promising candidates to clinical evaluation.
The Lab has also established common preclinical standards for the AIDS vaccine field and supports two consortia comprised of scientists from IAVI and academic institutions. Their goals are to understand the basis of naturally evoked, broadly neutralizing antibodies against HIV and to understand the mechanism for the strong protection of live attenuated SIV vaccination in non-human primates to inform the design of AIDS vaccine candidates.
Kinnos Inc. aims to raise the standard of infectious disease decontamination to protect healthcare workers, patients, and the general public. The company's first product, Highlight, is a point-of-use additive for existing disinfectants that eliminates human error and greatly increases visibility, coverage, and end-user compliance.
Lucerna, Inc. is a RNA-based research tool company that uses a fluorescent aptamer platform for the purpose of: 1.) Developing metabolite sensors for therapeutic diagnostics, 2.) Developing fluorescent assays against hard-to-access targets to enable high-throughput drug discovery, and 3.) Providing plug-and-play RNA imaging systems as research reagents.
Macrogen Corp. has been the corporate partner of choice on genomic sequencing for many academic and commercial organizations. The company's superior quality, cost effective business model and customer focused services allowed it to expand and grow into an international organization. Macrogen's twenty years of sequencing experience uniquely positions it to contribute in both the Sanger and the next generation genomic sequencing.
Mirimus is a high-tech business with the expertise in RNAi technologies required for development of superior tools for potent gene silencing, both in cells and animal models. Its advanced RNAi technologies are critical for the generation of animal models that can pave the way drugs are developed by pin-pointing potential toxicities and preventing harmful side-effects of therapeutics in patients. Mirimus is also engaged in the design, development and pioneering of new CRISPR/Cas9 genome editing technologies to develop advanced human disease models that are crucial for the preclinical evaluation of new therapeutics.
Modis Therapeutics, Inc.
Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. The company was formed in 2016 through a collaboration with academic experts in mitochondrial biology. Modis’ lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease.
New York Huaqi Bioengineering, LLC
New York Huaqi Bioengineering, LLC develops new products in modification or growth of liver organ in vitro to meet the shortage of liver organs in clinic.
Contact: Lili Xu, Founder & CEO (914-316-0801)
NIRx Medical Technologies, LLC
NIRx provides custom technology solutions to the investigative community for a wide range of NIRS imaging applications. While many of our systems are in the field of neuroscience (infants to adults), they are also used for investigation of breast cancer, peripheral vascular disease and the study of small animals.
Contact: Richard Barbour, Vice President (516-759-8750)
Paritic, Inc. provides 3D medical imaging navigation system for minimally invasive surgery. Paritic specializes in medical imaging software and hardware systems for clinical usage. Paritic offers intra-operative navigation system, as well as 3D imaging software products and services for surgical planning, surgical training, virtual surgery post-operative evaluation. With Paritic’s technology, surgery is becoming more secure, more accurate and more effective.
Contact: Yale Ji (212-901-8608) - firstname.lastname@example.org
Parkside Scientific, Inc.
Parkside Scientific Inc. is a privately-held NYC-based preclinical stage drug company that focuses on designing and developing novel drugs for cancers and inflammatory diseases that work through modulation of gene expression. Parkside’s competitive scientific advantages lie in its deep understanding of the biology of signaling proteins, and of the disease mechanisms of cancers and inflammatory disorders triggered by these proteins, and the ability of Parkside structurally to design compounds to prevent the triggering of disease conditions. Parkside is actively developing new drugs for multiple diseases with funding including a grant from the NIH aimed at triple-negative breast cancer, a deadly disease that has no targeted therapy.
Contact: Gary K. Duberstein, COO & General Counsel
Founded in 2016, Taithera, Inc. is developing a bone targeted drug delivery platform for the treatment of musculoskeletal disorders. Its first product is a targeted therapeutic for the treatment of breast cancer bone metastases. Taithera won First Place at the 2017 RESI Innovation Challenge.
Contact: Seth Harlem, CEO , email@example.com, 347-404-4408
Vasocure is a clinical-stage vascular therapeutics company with the world’s first peptide to directly treat neointimal disease and atherosclerosis.
XL Batteries has invented a flow battery with novel chemistry to address the challenges of grid-level energy storage. Among many advantages, its battery is projected to last for over 20 years; a lifetime necessary for infrastructure investment. XL Batteries has conducted long term tests and over 1000 cycles with 0% degradation. Additionally, it is simple to scale since it is a unique liquid battery. It is non-flammable since the solvent is salt water (pH 7). The company has a working, full battery prototype where the organic compounds, components, carbon electrodes, and membrane are all sourced from commodity chemicals and are orders of magnitude less expensive than lithium ion. XL Batteries' aim is to solve the longstanding challenge of grid level storage through an electrochemical battery without geographical limitations that is safe, scalable, and long-lasting.
Xylyx Bio is revolutionizing the $7B+ cell culture market with its first-in-class tissue-specific biomaterials, enabling faster, more accurate and actionable results for scientists working in pharmaceutical development, cell biology research and regenerative medicine. Rather than isolated components or synthetic materials, the Company’s innovative product platform provides a natural, physiological cell culture environment in which to develop, test and deliver treatments and cures to patients more quickly and less expensively.